12:00 AM
 | 
Nov 11, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cervarix: Additional Phase III data

Researchers at the National Cancer Institute (NCI) and colleagues reported additional data from the double-blind, Costa Rican Phase III CVT trial in females aged 18-25 showing that a 2-dose schedule of Cervarix administered at 0 and 6 months (n=52) led to HPV types 16 (520 vs. 748 EU/mL) and 18 (305 vs. 335 EU/mL) GMTs at 4 years that were non-inferior to a 3-dose schedule of Cervarix administered at 0, 1 and 6 months (n=120). Additionally, a 2-dose schedule of Cervarix administered at 0 and 1...

Read the full 420 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >